Sumitomo Chemical Co., Ltd. - Oct 1, 2021 Form 3 Insider Report for Roivant Sciences Ltd. (ROIV)

Role: 10%+ Owner
Signature: Sumitomo Dainippon Pharma Co., Ltd., By: /s/ Tsutomu Nakagawa, Name: Tsutomu Nakagawa, Title: Senior Director, Global Corporate Strategy
Stock symbol: ROIV
Transactions as of: Oct 1, 2021
Transactions value $: $0
Form type: 3
Date filed: 10/1/2021, 05:00 PM
Previous filing: Sep 30, 2021
Next filing: Mar 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ROIV	Common Shares						86.4M	Oct 1, 2021	See Footnote	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon") directly owns 86,367,360 Common Shares. Sumitomo Dainippon is a 51.78% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo"). Sumitomo may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitomo Dainippon owns. Sumitomo disclaims beneficial ownership of such reported securities except to the extent of its pecuniary interest therein.

Content

Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon") directly owns 86,367,360 Common Shares. Sumitomo Dainippon is a 51.78% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo"). Sumitomo may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitomo Dainippon owns. Sumitomo disclaims beneficial ownership of such reported securities except to the extent of its pecuniary interest therein.